Unusually Long Survival (More Than Five Years to More Than 31 Years) in Twelve Patients With Relapsed Medulloblastoma Treated With Antineoplastons in Phase II Studies. CLINICMED 2015, 6 (4), 1-8. https://doi.org/10.24018/clinicmed.2025.6.4.389.